» Articles » PMID: 38480681

High-resolution Cryo-EM of the Human CDK-activating Kinase for Structure-based Drug Design

Abstract

Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM). Here, we use high-resolution cryo-EM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division, in its free and nucleotide-bound states and in complex with 15 inhibitors at up to 1.8 Å resolution. Our structures provide detailed insight into inhibitor interactions and networks of water molecules in the active site of cyclin-dependent kinase 7 and provide insights into the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based drug design.

Citing Articles

Nucleotide Excision Repair: Insights into Canonical and Emerging Functions of the Transcription/DNA Repair Factor TFIIH.

Zachayus A, Loup-Forest J, Cura V, Poterszman A Genes (Basel). 2025; 16(2).

PMID: 40004560 PMC: 11855273. DOI: 10.3390/genes16020231.


Structural basis of undecaprenyl phosphate glycosylation leading to polymyxin resistance in Gram-negative bacteria.

Ashraf K, Bunoro-Batista M, Ansell T, Punetha A, Rosario-Garrido S, Firlar E bioRxiv. 2025; .

PMID: 39974898 PMC: 11838356. DOI: 10.1101/2025.01.29.634835.


Rapid structural analysis of bacterial ribosomes in situ.

Powell B, Brant T, Davis J, Mosalaganti S Commun Biol. 2025; 8(1):131.

PMID: 39875527 PMC: 11775198. DOI: 10.1038/s42003-025-07586-y.


Understanding the Cytomegalovirus Cyclin-Dependent Kinase Ortholog pUL97 as a Multifaceted Regulator and an Antiviral Drug Target.

Marschall M, Schutz M, Wild M, Socher E, Wangen C, Dhotre K Cells. 2024; 13(16.

PMID: 39195228 PMC: 11352327. DOI: 10.3390/cells13161338.


Structural basis of Cdk7 activation by dual T-loop phosphorylation.

Duster R, Anand K, Binder S, Schmitz M, Gatterdam K, Fisher R Nat Commun. 2024; 15(1):6597.

PMID: 39097586 PMC: 11297931. DOI: 10.1038/s41467-024-50891-z.


References
1.
Fisher R . Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci. 2005; 118(Pt 22):5171-80. DOI: 10.1242/jcs.02718. View

2.
Fisher R . Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription. 2018; 10(2):47-56. PMC: 6602562. DOI: 10.1080/21541264.2018.1553483. View

3.
Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittrager I, Bahsi H . A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015; 59(4):2062-71. PMC: 4356785. DOI: 10.1128/AAC.04534-14. View

4.
Patel H, Periyasamy M, Sava G, Bondke A, Slafer B, Kroll S . ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018; 17(6):1156-1166. PMC: 5985928. DOI: 10.1158/1535-7163.MCT-16-0847. View

5.
Hu S, Marineau J, Rajagopal N, Hamman K, Choi Y, Schmidt D . Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7. Cancer Res. 2019; 79(13):3479-3491. DOI: 10.1158/0008-5472.CAN-19-0119. View